3Collet JP, Montalescot G, Lison L, et al. Percutaueous coronary interven- tion after subcutaeous enoxparin pretreatment inpatients with unstable an- ginapectoris. Circulation ,2001,103:658-663.
4Dumaine R, Borentain M, Bertel O, et al. Intravenous low-molecular- weight heparinscompared with unfractionated heparin in percutaneous coronary intervention : quantitative review of randomized trials. Arch Intern Med ,2007,167:2423-2430.
5Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention : the pharmacokinetics of enoxaparin in PCI study. Catheter Cardiovase Interv, 2004,61 : 163-170.
7Cohen M, Theroux P, Borzak S, et al. Randomized doubleblind safety study of enoxaparin versus unf ractionated heparin in patients with non- ST-segment elevation acute coronary syndromest reared with tirofiban and aspirin : tlle ACUTE II study. The Antit hrombofie Combination Using Tirofiban and Enoxaparin. Am Heart J,2002,144 : 470-477.
8Goodman SG, Fitchett D, Armstrong FW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patient s with non-ST-segment elevation acute coronary syn- dromes receiving the glyceprotein Ⅱ b/Ⅲ a inhibiter eptifibatide. Circula- tion ,2003,107:238-244.
9Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enox- aparin vs unfractionated heparin in patient s with non-ST-segment eleva- tion acute coronary syndromes who receive tirofiban and aspirin: a ran- domized cont rolled trial. JAMA,2004,292:55-64.
10Ferguson JJ, Calif RM, Antman EM, et al. Enoxaparin vs unfraetionated heparin in high-risk patient s with non-ST-segment elevation acute coro- nary syndromes managed with an intended early iuvasive strategy : prima- ry results of the SYNERGY randomized trial. JAMA,2004,292:45-54.
3吕辰.依诺肝素治疗冠状动脉疾病的临床潜力[J].Foreign Medical Sciences Section on Pharmacy,1999,26(4):210-210.
4Hish J R,Aschke R.Hepariu.and.low-molecular-Weight[J].Chest,2004,126:188S-203 S.
5Sundaram M,Qi Y,Shriver Z,et al.Rational design of low molecular weight heparns with improved in vivo activity[J].PNAS,2003,100:651-656.
6Gambaro G,Cavizana A D.Luzi P,et al.Glylosaminoglycans morphological renal alterations and albuminuria in diabetic rats[J].Kidney Int,1992,42:285-287.
7Pross M,Lippert H,Nester G,et al.Effect of low molecular weight heparin on intra-abdominal metastasis in a lapavoscopic experinental study[J].Int J Colorectal Dis,2004,19:143 -146.
8Bobek V,Kovarik J.Antitumor and anxtimetastatic effect of warfarin and heparin[J].Biomed pharmacother,2004,58:213 -219.
9Deepa P R,Varalakshmi P.Protective effects of certopar in sodium,a low molecular weight heparin derivative,inexperimental atherosclerosis[J].Clinchim Acta,2004,339:105-115.
10Abdel-Salam O M,Baiuomy A R,Ameen A,et al.A Study of unfractionated and low molecular weight heparins in amodel of cholestatic liver injury in therat[J].PharmacolRes,2005,51:59-67.
